Foreign media: Global pharmaceutical giants are increasing investments in Chinese biotech companies to tap into innovation capabilities and valuation growth potential. At the Hong Kong Global Health Summit, the head of CITIC Securities' Healthcare Group stated that multinational pharmaceutical companies are shifting their China operations from capital-intensive models toward investing in local firms with strong innovation capacity and high integration levels, a move that helps Chinese enterprises grow and participate in global competition.
Specific examples include: On Wednesday, AstraZeneca announced the establishment of a joint venture with Sinopharm Group to build a pharmaceutical production base in Shijiazhuang, Hebei Province, with AstraZeneca holding a 49% stake, initially focusing on manufacturing and supply for global markets; in May this year, Swedish Munkedal Medical and Zhejiang Zhende Medical established a joint venture, integrating their business portfolios and jointly developing future products.
Original source: toutiao.com/article/1872970046898176/
Disclaimer: The views expressed in this article are solely those of the author.